Anebulo Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $13.1M
- Price
- $0.32
- % Change (Daily % change from the live per-ticker quote feed.)
- 0.00%
- Volume
- 100
About
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
Quick stats
Shares outstanding40.8M
Computed float7.3M
Float / shares17.8%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001815974
Websitehttps://www.anebulo.com
AI Summary
AI-generated23d agoAnebulo Pharmaceuticals (ANEB) to Announce Earnings on Wednesday
Anebulo Pharmaceuticals (NASDAQ: ANEB - Get Free Report) is anticipated to post its Q4 2026 resultson Wednesday, September 23rd. Analysts expect the company to announce earnings of ($0.10) per share for the quarter. Investors can check the company's upcoming Q4 2026 earning overview page for the latest details on the call scheduled for Tuesday, September 22,